Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.

Chevalier Y, Quek E, Borah B, Gross G, Stewart J, Lang T, Zysset P

Bone1 Oct 2009Cited by 47 (Europe PMC)

PMID19800436DOI10.1016/j.bone.2009.09.032PepBankPUB-19800436

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialActivity measurement
In postmenopausal women with osteoporosis, 12 months of teriparatide following prior risedronate or alendronate increased BMD-derived bone volume fraction from baseline.
In plain wordsIn women with osteoporosis, estimated bone volume fraction rose from baseline after 12 months of teriparatide that followed alendronate or risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBMD-derived bone volume fraction
Study
n = 171
CT-based L1 vertebral finite element models
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The results of this study demonstrated that 12 months of treatment with teriparatide following prior treatment with either risedronate or alendronate increased BMD-derived BV/TV(d), the predicted vertebral stiffness, and failure load.
1 context sentence(design, population, supporting numbers)
Summary · context
Finite element models of the L1 vertebra were created from quantitative CT scans, acquired before and after 12 months of therapy with teriparatide, from 171 patients from the OPTAMISE study.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1980043601
02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyActivity measurement
In vertebral models, BMD-derived bone volume fraction increased more with teriparatide after prior risedronate than after prior alendronate.
In plain wordsIn women with osteoporosis, estimated bone volume gains with teriparatide were larger after prior risedronate than after prior alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone volume fraction increase by prior treatment
Study
n = 171
CT-based L1 vertebral finite element models
Comparator
Prior alendronate treatment
Outcome group
Bone and joint · Musculoskeletal
Measurements
BV/TV(d) increase
6.9%
prior risedronate
BV/TV(d) increase
4.6%
prior alendronate
Source sentences
Summary
The mechanical variables increased in greater proportion than BV/TV(d), which increased by 6.9+/-0.9% versus 4.6+/-0.8% in the prior-risedronate and prior-alendronate groups, respectively (p=0.0290).
1 context sentence(design, population, supporting numbers)
Summary · context
Finite element models of the L1 vertebra were created from quantitative CT scans, acquired before and after 12 months of therapy with teriparatide, from 171 patients from the OPTAMISE study.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1980043606
03Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoActivity measurement
In vertebral models from women receiving teriparatide, predicted stiffness increased after prior risedronate or alendronate treatment.
In plain wordsIn computer models, predicted vertebral stiffness increased compared with baseline during teriparatide treatment after either prior drug.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePredicted vertebral stiffness
Study
humann = 171
CT-based L1 vertebral finite element models
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The results of this study demonstrated that 12 months of treatment with teriparatide following prior treatment with either risedronate or alendronate increased BMD-derived BV/TV(d), the predicted vertebral stiffness, and failure load.
1 context sentence(design, population, supporting numbers)
Summary · context
Finite element models of the L1 vertebra were created from quantitative CT scans, acquired before and after 12 months of therapy with teriparatide, from 171 patients from the OPTAMISE study.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1980043602
04Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoActivity measurement
In vertebral models from women receiving teriparatide, failure load increased after prior risedronate or alendronate treatment.
In plain wordsIn computer models, predicted vertebral failure load increased compared with baseline during teriparatide treatment after either prior drug.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePredicted vertebral failure load
Study
humann = 171
CT-based L1 vertebral finite element models
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The results of this study demonstrated that 12 months of treatment with teriparatide following prior treatment with either risedronate or alendronate increased BMD-derived BV/TV(d), the predicted vertebral stiffness, and failure load.
1 context sentence(design, population, supporting numbers)
Summary · context
Finite element models of the L1 vertebra were created from quantitative CT scans, acquired before and after 12 months of therapy with teriparatide, from 171 patients from the OPTAMISE study.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1980043603
05Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoActivity measurement
In vertebral models, stiffness increased more with teriparatide after prior risedronate than after prior alendronate.
In plain wordsIn computer models, teriparatide-associated stiffness gains were greater after prior risedronate than after prior alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseStiffness increase by prior treatment
Study
humann = 171
CT-based L1 vertebral finite element models
Comparator
Prior alendronate treatment
Outcome group
Bone and joint · Musculoskeletal
Measurements
Stiffness increase
24.6%
prior risedronate
Stiffness increase
14.4%
prior alendronate
Source sentences
Summary
The mean (+/-standard error) increase in stiffness was greater in the prior risedronate group than the prior alendronate group (24.6+/-3.2% versus 14.4+/-2.8%, respectively; p=0.0073).
1 context sentence(design, population, supporting numbers)
Summary · context
Finite element models of the L1 vertebra were created from quantitative CT scans, acquired before and after 12 months of therapy with teriparatide, from 171 patients from the OPTAMISE study.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1980043604
06Computer modelNot a test of Teriparatide (PTH 1-34) aloneIn silicoActivity measurement
In vertebral models, failure load increased more with teriparatide after prior risedronate than after prior alendronate.
In plain wordsIn computer models, teriparatide-associated failure load gains were greater after prior risedronate than after prior alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFailure load increase by prior treatment
Study
humann = 171
CT-based L1 vertebral finite element models
Comparator
Prior alendronate treatment
Outcome group
Bone and joint · Musculoskeletal
Measurements
Failure load increase
27.2%
prior risedronate
Failure load increase
15.3%
prior alendronate
Source sentences
Summary
Similarly, vertebral failure load increased by 27.2+/-3.5% in the prior risedronate group versus 15.3+/-3.1% in the prior alendronate group (p=0.0042).
1 context sentence(design, population, supporting numbers)
Summary · context
Finite element models of the L1 vertebra were created from quantitative CT scans, acquired before and after 12 months of therapy with teriparatide, from 171 patients from the OPTAMISE study.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1980043605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.